What are current treatment options for Cyclosporiasis for those that have a Bactrim allergy?

Comment by InpharmD Researcher

Cyclosporiasis treatment options for patients with a sulfonamide (Bactrim/TMP-SMX) allergy are limited, as no alternative has demonstrated efficacy comparable to TMP-SMX. Current CDC guidance states that no highly effective alternative has been identified and suggests symptomatic management, use of an alternative antimicrobial supported by limited evidence, or TMP-SMX desensitization in carefully selected patients with non–life-threatening sulfonamide allergy who require treatment. Available guidelines and review articles consistently identify ciprofloxacin as the preferred alternative when TMP-SMX cannot be used, although it is generally considered less effective. Nitazoxanide has also been reported as a potential option for patients who cannot tolerate sulfonamides or who do not respond to ciprofloxacin; however, supporting evidence is limited and its efficacy has been inconsistent. Other antimicrobials, including albendazole, azithromycin, doxycycline, metronidazole, tetracycline, tinidazole, trimethoprim alone, and norfloxacin, have not demonstrated reliable efficacy and are not recommended. Supportive care with fluid and electrolyte replacement should also be provided as clinically indicated.
Background

The CDC clinical guidance on clinical care of cyclosporiasis states that no highly effective alternative has been identified for patients with a sulfonamide allergy or intolerance. Potential approaches include observation and symptomatic management, use of an antibiotic supported by limited evidence, or trimethoprim-sulfamethoxazole (TMP-SMX) desensitization in carefully selected patients who require treatment, have been evaluated by an allergist, and do not have a life-threatening allergy. The CDC notes that ciprofloxacin has shown only modest activity in a small study of patients with HIV and has generally been ineffective in immunocompetent patients, while several other antimicrobials, including nitazoxanide, albendazole, azithromycin, doxycycline, metronidazole, tetracycline, tinidazole, and trimethoprim alone, have not demonstrated reliable efficacy. Similarly, the American Family Physician review states that no effective alternative has been identified for patients with sulfa allergy or intolerance, noting that nitazoxanide and other antibiotics have been cited as potential alternatives but are associated with higher failure rates. [1], [2]

The National Institutes of Health (NIH), the HIV Medicine Association (HIVMA), and the Infectious Diseases Society of America (IDSA) Joint Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV identify TMP-SMX as the preferred therapy for acute infection of Cystoisospora belli Infection; however, for patients with sulfa intolerance or allergy, the recommended alternative is pyrimethamine 50–75 mg orally once daily plus leucovorin 10–25 mg orally once daily for 4 weeks (BIII). Ciprofloxacin 500 mg orally (or 400 mg IV if oral therapy is not tolerated) twice daily for 7 days is listed as a second-line alternative (CI). The guideline also notes that leucovorin should be coadministered with pyrimethamine to reduce the risk of myelosuppression, and that ciprofloxacin may increase the QTc interval and has been associated with tendon rupture and aortic aneurysms. Supportive care, including fluid and electrolyte replacement for dehydration and nutritional supplementation in malnourished patients, is also recommended as appropriate. [3]

The 2019 American Society of Transplantation (AST) Infectious Diseases Community of Practice guideline recommends TMP-SMX as the preferred treatment for Cyclospora infection in solid organ transplant recipients. For patients with sulfonamide intolerance or allergy, the guideline recommends ciprofloxacin 500 mg orally twice daily for 7 days, followed by 500 mg three times weekly for secondary prophylaxis. The guideline notes that this recommendation applies to both Cyclospora and Cystoisospora infections, although it acknowledges that the optimal duration of secondary prophylaxis is unknown. In addition, reduction of immunosuppression, when feasible, is recommended as part of management in transplant recipients with these infections. [4]

Available review articles on cyclosporiasis treatment similarly identify ciprofloxacin as the primary alternative for patients with sulfonamide allergy or intolerance, although they consistently note that it is less effective than TMP-SMX. One review describes a regimen of ciprofloxacin 500 mg orally twice daily for 7 days followed by three times weekly for 2 weeks in transplant recipients, while another notes its suitability for patients unable to tolerate sulfonamides. Both reviews also discuss nitazoxanide as a potential option for patients with sulfonamide intolerance or for those who do not respond to ciprofloxacin, but emphasize that supporting evidence is limited and that its efficacy has been inconsistent. Additionally, available evidence indicates that norfloxacin, metronidazole, and tinidazole have not demonstrated efficacy for the treatment of cyclosporiasis. [5], [6]

Background References: [1] Centers for Disease Control and Prevention (CDC). Clinical care of cyclosporiasis. Updated March 8, 2024. Accessed July 9, 2026. https://www.cdc.gov/cyclosporiasis/hcp/clinical-care/index.html
[2] Kucik CJ, Martin GL, Sortor BV. Common intestinal parasites. Am Fam Physician. 2004;69(5):1161-1168.
[3] Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. National Institutes of Health; HIV Medicine Association; Infectious Diseases Society of America. Updated May 27, 2026. Accessed July 9, 2026.
[4] La Hoz RM, Morris MI; AST Infectious Diseases Community of Practice. Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13618. doi:10.1111/ctr.13618
[5] Giangaspero A, Gasser RB. Human cyclosporiasis. Lancet Infect Dis. 2019;19(7):e226-e236. doi:10.1016/S1473-3099(18)30789-8
[6] Li J, Wang R, Chen Y, Xiao L, Zhang L. Cyclospora cayetanensis infection in humans: biological characteristics, clinical features, epidemiology, detection method and treatment. Parasitology. 2020;147(2):160-170. doi:10.1017/S0031182019001471
Literature Review

A search of the published medical literature revealed 2 studies investigating the researchable question:

What are current treatment options for Cyclosporiasis for those that have a Bactrim allergy?

Level of evidence

C - Multiple studies with limitations or conflicting results  Read more→


Please see Tables 1-2 for your response.

Trimethoprim–Sulfamethoxazole Compared with Ciprofloxacin for Treatment and Prophylaxis of Isospora belli and Cyclospora cayetanensis Infection in HIV-Infected Patients
Design

Randomized, controlled trial

N= 42
Objective To compare 1 week of trimethoprim–sulfamethoxazole treatment and 1 week of ciprofloxacin treatment in HIV-infected patients with chronic diarrhea caused by I. belli and C. cayetanensis
Study Groups

Trimethoprim–sulfamethoxazole (n= 19)

Ciprofloxacin (n= 23)
Inclusion Criteria HIV-infected patients aged 18 to 60 years with chronic diarrhea due to I. belli or C. cayetanensis, identified on two occasions within 10 days before initiation of therapy
Exclusion Criteria Pregnant women, persons who had received ciprofloxacin or trimethoprim–sulfamethoxazole within 2 weeks of enrollment, and patients with other enteric pathogens
Methods Patients were randomly assigned to receive oral trimethoprim–sulfamethoxazole (160 mg or 800 mg) or ciprofloxacin (500 mg) twice daily for 7 days. Stool examination was repeated on days 3 and 7. Patients with complete response received prophylaxis for 10 weeks (1 tablet orally, three times per week). 
Duration January 1997 to August 1998
Outcome Measures Cessation of diarrhea and negative stool examination at day 7 
Baseline Characteristics   Trimethoprim–Sulfamethoxazole (n= 19) Ciprofloxacin (n= 23)
Age, years 29 29
Male 57% 57%
Duration of diarrhea, months 4.3 4.3
Weight loss >10% 40% 40%
Prior AIDS-defining illness 40% 40%
Results   Trimethoprim–Sulfamethoxazole Group (n= 19) Ciprofloxacin Group (n= 23)
Cessation of diarrhea by day 7 19 (100%) 20 (87%)
Negative results on stool examination at day 7 18 (95%) 16 (69%)

Isosporiasis: No recurrences were observed during the 10-week period.

Cyclosporiasis: No recurrences were observed in the trimethoprim–sulfamethoxazole group, but 1 of 7 patients receiving ciprofloxacin had a recurrence after 4 weeks.
Adverse Events No patients discontinued therapy due to side effects.
Study Author Conclusions A 1-week course of trimethoprim–sulfamethoxazole is effective in HIV-infected patients with cyclosporiasis or isosporiasis. Although ciprofloxacin is not as effective, it is acceptable for patients who cannot tolerate trimethoprim–sulfamethoxazole.
Critique The study provides valuable insights into the treatment of isosporiasis and cyclosporiasis in HIV-infected patients, demonstrating the efficacy of a reduced dose of trimethoprim–sulfamethoxazole. However, the small sample size and single-center design may limit the generalizability of the findings. Additionally, the study did not include a placebo group, which could have strengthened the conclusions.
Table 1 References:
[7] Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med. 2000;132(11):885-888. doi:10.7326/0003-4819-132-11-200006060-00006

 

Efficacy of Nitazoxanide for Cyclosporiasis in Patients with Sulfa Allergy

Design

 Case Report 

Case presentation

A 40-year-old woman with a history of hypothyroidism and asthma presented with profuse, watery diarrhea persisting over several days. She denied symptoms of fever, bloating, nausea, or vomiting and reported no recent travel or contact with ill individuals. Her household had recently increased consumption of fresh fruits and vegetables, yet no family members reported similar symptoms. Physical examination yielded normal results. Initial stool cultures and examinations for ova and parasites were conducted, and she was discharged with ciprofloxacin treatment. Despite treatment, her condition did not improve, leading to a follow-up at the infectious diseases clinic. Modified acid-fast staining of her stool confirmed the presence of Cyclospora cayetanensis oocysts. Due to a severe allergy to sulfa drugs, she was prescribed nitazoxanide. After seven days of treatment, her symptoms subsided, and follow-up stool examinations showed normal results. While no specific food source of Cyclospora was identified, the recent dietary change to include more fresh produce, particularly berries, could have been a potential source. No additional cases related to her infection were reported.

Study Author Conclusions

 Although C. cayetanensis is an unusual cause of diarrhea in the United States, it has emerged as an important cause of outbreaks of foodborne disease and can be found sporadically in immunocompetent people, such as our patient. Nitazoxanide represents an important treatment option for patients who have a sulfa allergy or for whom treatment with a sulfa or ciprofloxacin has failed.
Table 2 References:
[8] Zimmer SM, Schuetz AN, Franco-Paredes C. Efficacy of nitazoxanide for cyclosporiasis in patients with sulfa allergy. Clin Infect Dis. 2007;44(3):466-467. doi:10.1086/510744